Lesion size, patient age, and current ipsilateral breast cancer are statistically significant predictors of pathologic outcome for nonmasslike enhancement lesions seen on breast MRI, according to a scientific session presented on Sunday at the RSNA 2009 meeting.
Lesion size, patient age, and current ipsilateral breast cancer are statistically significant predictors of pathologic outcome for nonmasslike enhancement lesions seen on breast MRI, according to a scientific session presented on Sunday at the RSNA 2009 meeting.
Nonmasslike enhancement lesions (NMLE) show up regularly on breast MRI, and the current study, by Dr. Eugene Ong, a radiologist in Singapore, validates specific BI-RADS modifiers for the lesions.
In the prospective study of 565 MR-guided breast biopsy cases, 215 cases were reported as NMLE. Of those lesions, 159 were benign and 46 were malignant. Nearly half of the malignant lesions (53.6%) were in situ carcinoma and the rest were invasive. There was no difference in average size of malignant (3 cm) and benign NMLE (2.5 cm). However, the researchers found lesions greater than 4 cm were more likely to be malignant.
Another interesting factor for predictors of outcome was age. The mean patient ages for benign and malignant lesions were 48 years and 55 years, respectively.
Lastly, ipsilateral breast cancer played a role in pathologic outcome. A greater proportion of malignant NMLE was found in patients with ipsilateral breast cancer compared with all other patients, Ong said.
In 35 cases with NMLE ipsilateral to a recent breast cancer, 45% were malignant.
The most common internal enhancement patterns for the lesions were clumped, followed by heterogeneous, which accounted for 80.5% of all NMLE. The positive predictive value was 28% for each.
Can Abbreviated Breast MRI Have an Impact in Assessing Post-Neoadjuvant Chemotherapy Response?
April 24th 2025New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.
Could Ultrafast MRI Enhance Detection of Malignant Foci for Breast Cancer?
April 10th 2025In a new study involving over 120 women, nearly two-thirds of whom had a family history of breast cancer, ultrafast MRI findings revealed a 5 percent increase in malignancy risk for each second increase in the difference between lesion and background parenchymal enhancement (BPE) time to enhancement (TTE).